Using machine learning and lab validation, researchers identified a peptide (FPRPFL) from highland barley protein that inhibits ACE with an IC50 of just 1.18 μM, making it a promising natural antihypertensive candidate.
IC50 = 1.18 μMThe barley-derived peptide FPRPFL inhibits the ACE enzyme at very low concentrations, comparable to or better than many other food-derived ACE-inhibitory peptides
What the researchers found
The machine learning pipeline (using Gradient Boosted Decision Trees) successfully predicted ACE-inhibitory peptides from papain-hydrolyzed highland barley protein. The peptide FPRPFL was identified as the most potent ACE inhibitor with an IC50 of 1.18 μM. Enzyme inhibition kinetics, circular dichroism, molecular docking, and molecular dynamics simulations characterized its binding mechanism. Network pharmacology analysis revealed multi-target, multi-pathway antihypertensive properties. The peptide also showed stability in simulated digestion conditions.
Why it matters
Hypertension affects over a billion people worldwide, and many current ACE inhibitors cause side effects like dry cough. Natural food-derived peptides could offer blood pressure management with fewer side effects. This study's combination of AI-driven discovery with thorough lab validation creates a scalable pipeline for finding bioactive peptides — potentially opening the door to functional foods or supplements derived from common crops like barley.
How the study worked
Four machine learning models were trained to predict ACE-inhibitory capacity of peptides, with Gradient Boosted Decision Trees (GBDT) performing best. Highland barley protein was hydrolyzed with papain and the resulting peptides were screened computationally. Top candidates were validated through in vitro ACE inhibition assays, enzyme kinetics, and simulated digestion stability tests. Binding mechanisms were analyzed using circular dichroism, molecular docking, and molecular dynamics simulations. Network pharmacology mapped the peptide's multi-target interactions.
What this study cannot tell us
All validation was in vitro — no animal or human studies were conducted. The IC50 value, while impressive in a lab setting, doesn't account for bioavailability, absorption, and metabolism in a living organism. Simulated digestion stability doesn't fully replicate real gastrointestinal conditions. The network pharmacology predictions of multi-target activity are computational and require experimental confirmation. Highland barley protein availability and processing costs for industrial-scale production were not addressed.
How to read the evidence
This is an in vitro study with computational validation. While the ML pipeline and lab experiments are rigorous, the lack of any in vivo data means the peptide's real-world blood pressure-lowering potential is unconfirmed.
When this study was published
Published in 2025, this study represents the cutting edge of AI-driven bioactive peptide discovery, combining modern machine learning with traditional food science approaches.
The bigger picture
This study exemplifies the convergence of artificial intelligence and bioactive peptide research. Traditional peptide discovery is slow and expensive, but ML-based screening can evaluate thousands of candidates rapidly. As food-derived bioactive peptides gain interest for chronic disease management, this pipeline approach — from grain protein to validated ACE inhibitor — could be applied to many other food sources and therapeutic targets, accelerating the development of peptide-based functional foods and nutraceuticals.
Questions still open
- Does the FPRPFL peptide maintain its ACE-inhibitory potency when consumed orally and subjected to real digestive conditions?
- How does its blood pressure-lowering effect in animal models compare to established ACE inhibitors?
- Could highland barley-based functional foods deliver meaningful quantities of this peptide for blood pressure management?
Common questions
What is ACE and why do blood pressure drugs target it?
Could eating highland barley lower blood pressure?
Read the original research
Machine learning discovery of novel antihypertensive peptides from highland barley protein inhibiting angiotensin I-converting enzyme (ACE).
Food research international (Ottawa, Ont.), 202, 115689
Citation
Bao, Xin; Zhang, Yiyun; Wang, Liyang; Dai, Zijian; Zhu, Yiqing; Huo, Mengyao; Li, Rong; Hu, Yichen; Shen, Qun; Xue, Yong. (2025). Machine learning discovery of novel antihypertensive peptides from highland barley protein inhibiting angiotensin I-converting enzyme (ACE).. Food research international (Ottawa, Ont.), 202, 115689. https://doi.org/10.1016/j.foodres.2025.115689